Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Kahl on ADCT-402 for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Brad S. Kahl, MD
Published: Wednesday, Jun 14, 2017



Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.

ADCT-402 is a novel antibody-drug conjugate targeting CD19, explains Kahl. In the dose-escalation trial, there have been over 60 patients enrolled.

Overall response rates have been seen to be around 60% with complete response rates at approximately 40%. This is impressive looking at the patient population for this study, where there are currently no beneficial treatments existing, states Kahl.
 


Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.

ADCT-402 is a novel antibody-drug conjugate targeting CD19, explains Kahl. In the dose-escalation trial, there have been over 60 patients enrolled.

Overall response rates have been seen to be around 60% with complete response rates at approximately 40%. This is impressive looking at the patient population for this study, where there are currently no beneficial treatments existing, states Kahl.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x